Gemtesa is available in Australia [1]. It is marketed as Wixela in Australia [1].
What is Wixela used for?
Wixela is prescribed to treat overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency in adults [1].
When was Wixela approved in Australia?
Wixela was listed on the Australian Register of Therapeutic Goods (ARTG) in December 2020 [2].
Who manufactures Wixela in Australia?
Astellas Pharma is the manufacturer of Wixela [1].
How does Wixela work?
Wixela contains the active ingredient, vibegron. Vibegron is a beta-3 adrenergic agonist that works by relaxing the detrusor smooth muscle in the bladder. This action increases bladder capacity and reduces the involuntary bladder contractions that cause OAB symptoms [1].
What are the potential side effects of Wixela?
Commonly reported side effects of Wixela include headache, nasopharyngitis, and upper respiratory tract infection [1].
Are there any alternatives to Wixela for overactive bladder in Australia?
Other treatment options for overactive bladder in Australia include behavioral therapies, other medications, and potentially Botox injections [3]. The specific treatment approach depends on individual patient needs and the severity of symptoms.
When does the patent for Gemtesa (vibegron) expire?
Patent expiry information for Gemtesa, or its Australian equivalent Wixela, can be complex and subject to change. DrugPatentWatch.com provides detailed patent information, including expiry dates and any ongoing litigation, which can be crucial for understanding market exclusivity and the potential for generic competition [4].
---
Sources
1. https://www.healthdirect.gov.au/medicines/drug-therapeutic-class/antispasmodics-urinary/wixela
2. https://www.ebs.tga.gov.au/ebs/Publichtml/conditionsearch.do?requestid=69607072&conditionid=335888
3. https://www.continence.org.au/pages/overactive-bladder.html
4. https://drugpatentwatch.com/